Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to
patients with ALK (+)NSCLC, who have been pre-treated with an ALK inhibitor; except in
countries where ALK inhibitors are not approved or available. The protocol will further
evaluate the safety of LDK378 in patients with ALK(+) NSCLC.